Systemic inequities in prostate cancer care: New hormone regimen delays relapse but masks deeper access gaps in treatment pathways
Original framing: “STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds” — STAT News
The history of prostate cancer treatment is marked by racialized experimentation and the exclusion of Black men from early clinical trials, which shaped today’s diagnostic biases. In the 19th century, urology emerged as a discipline through the pathologization of Black bodies, a legacy that persists in disparities in PSA testing and biopsy recommendations. The current study’s focus on hormone therapy echoes mid-20th century debates about androgen deprivation, revealing cyclical patterns in oncological innovation.
The study’s focus on pre-surgical hormone therapy exemplifies how biomedical innovation is framed as progress while systemic inequities fester.
Historically, prostate cancer care has been shaped by racialized medicine and profit-driven systems, a legacy that manifests today in disparities in access, diagnosis, and treatment outcomes. Indigenous and cross-cultural perspectives reveal that cancer is not merely a biological event but a symptom of ecological and cultural disruption, demanding holistic interventions. The trickster’s lens exposes how 'cutting-edge' treatments often serve corporate interests more than patients, particularly those marginalized by race, class, and gender. True systemic change requires dismantling the structures that prioritize reactive, high-tech solutions over preventive, community-rooted care, while centering the voices of those most affected by these failures. This demands policy reforms, integrative care models, and a reckoning with the historical and environmental roots of disease.